Cancer Immunotherapy: the Beginning of the End of Cancer?

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2016 May 7

PMID 27151159

Citations 499

Authors

Sofia Farkona

Eleftherios P Diamandis

Ivan M Blasutig

Affiliations

Soon will be listed here.

Abstract

These are exciting times for cancer immunotherapy. After many years of disappointing results, the tide has finally changed and immunotherapy has become a clinically validated treatment for many cancers. Immunotherapeutic strategies include cancer vaccines, oncolytic viruses, adoptive transfer of ex vivo activated T and natural killer cells, and administration of antibodies or recombinant proteins that either costimulate cells or block the so-called immune checkpoint pathways. The recent success of several immunotherapeutic regimes, such as monoclonal antibody blocking of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD1), has boosted the development of this treatment modality, with the consequence that new therapeutic targets and schemes which combine various immunological agents are now being described at a breathtaking pace. In this review, we outline some of the main strategies in cancer immunotherapy (cancer vaccines, adoptive cellular immunotherapy, immune checkpoint blockade, and oncolytic viruses) and discuss the progress in the synergistic design of immune-targeting combination therapies.

Citing Articles

Research trends and highlights in PD-1/PD-L1 inhibitor immunotherapy in lung cancer: a bibliometric analysis.

Gu Z, Deng E, Ai J, Wu F, Su Q, Yu J Discov Oncol. 2025; 16(1):292.

PMID: 40064803 PMC: 11893958. DOI: 10.1007/s12672-025-02052-x.

Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy.

Gierschek F, Schlueter J, Kuhnel I, Feigl F, Schmiedel D, Prufer M Transfus Med Hemother. 2025; 52(1):42-60.

PMID: 39944413 PMC: 11813277. DOI: 10.1159/000540962.

Innovative CDR grafting and computational methods for PD-1 specific nanobody design.

Devasani J, Guntuku G, Panatula N, Muthyala M, Palla M, Siahaan T Front Bioinform. 2025; 4:1488331.

PMID: 39897125 PMC: 11782559. DOI: 10.3389/fbinf.2024.1488331.

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.

Wang M, Yu F, Zhang Y Mol Cancer. 2025; 24(1):26.

PMID: 39827147 PMC: 11748575. DOI: 10.1186/s12943-024-02214-5.

Genomic profiles and their associations with microsatellite instability status, tumor mutational burden, and programmed death ligand 1 expression in Chinese patients with colorectal cancer.

Luo B, Liao M, Nie B, Yu Y, Yao Q J Gastrointest Oncol. 2025; 15(6):2460-2472.

PMID: 39816034 PMC: 11732342. DOI: 10.21037/jgo-24-748.

References

Cohen A, Schaer D, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim S . Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One. 2010; 5(5):e10436. PMC: 2862699. DOI: 10.1371/journal.pone.0010436. View

DeWeese T, Van der Poel H, Li S, Mikhak B, Drew R, Goemann M . A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001; 61(20):7464-72. View

Verbrugge I, Hagekyriakou J, Sharp L, Galli M, West A, McLaughlin N . Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 2012; 72(13):3163-74. DOI: 10.1158/0008-5472.CAN-12-0210. View

Sharma P, Allison J . Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015; 161(2):205-14. PMC: 5905674. DOI: 10.1016/j.cell.2015.03.030. View

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Curran M, Montalvo W, Yagita H, Allison J . PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107(9):4275-80. PMC: 2840093. DOI: 10.1073/pnas.0915174107. View

Melero I, Berman D, Aznar M, Korman A, Perez Gracia J, Haanen J . Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015; 15(8):457-72. DOI: 10.1038/nrc3973. View

Gattinoni L, Finkelstein S, Klebanoff C, Antony P, Palmer D, Spiess P . Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005; 202(7):907-12. PMC: 1397916. DOI: 10.1084/jem.20050732. View

Huang J, Zhang S, Choi K, Choi I, Kim J, Lee M . Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther. 2009; 18(2):264-74. PMC: 2839296. DOI: 10.1038/mt.2009.205. View

10.

Kaufman H, Kohlhapp F, Zloza A . Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015; 14(9):642-62. PMC: 7097180. DOI: 10.1038/nrd4663. View

11.

Ishida Y, Agata Y, Shibahara K, Honjo T . Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11):3887-95. PMC: 556898. DOI: 10.1002/j.1460-2075.1992.tb05481.x. View

12.

Zamarin D, Holmgaard R, Subudhi S, Park J, Mansour M, Palese P . Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014; 6(226):226ra32. PMC: 4106918. DOI: 10.1126/scitranslmed.3008095. View

13.

Chiocca E, Rabkin S . Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014; 2(4):295-300. PMC: 4303349. DOI: 10.1158/2326-6066.CIR-14-0015. View

14.

Lynch T, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R . Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012; 30(17):2046-54. DOI: 10.1200/JCO.2011.38.4032. View

15.

Derre L, Rivals J, Jandus C, Pastor S, Rimoldi D, Romero P . BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest. 2009; 120(1):157-67. PMC: 2799219. DOI: 10.1172/JCI40070. View

16.

Palucka K, Banchereau J . Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013; 39(1):38-48. PMC: 3788678. DOI: 10.1016/j.immuni.2013.07.004. View

17.

Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee S, Yu J . Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A. 2006; 103(34):12873-8. PMC: 1568940. DOI: 10.1073/pnas.0605496103. View

18.

Lichty B, Breitbach C, Stojdl D, Bell J . Going viral with cancer immunotherapy. Nat Rev Cancer. 2014; 14(8):559-67. DOI: 10.1038/nrc3770. View

19.

Takeda K, Kojima Y, Uno T, Hayakawa Y, Teng M, Yoshizawa H . Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J Immunol. 2010; 184(10):5493-501. DOI: 10.4049/jimmunol.0903033. View

20.

Lee Y, Kim J, Choi K, Choi I, Kim H, Cho S . Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res. 2006; 12(19):5859-68. DOI: 10.1158/1078-0432.CCR-06-0935. View